-
公开(公告)号:US20240315994A1
公开(公告)日:2024-09-26
申请号:US18441446
申请日:2024-02-14
Applicant: ARPEGGIO BIOSCIENCES, INC.
Inventor: Timothy READ , Zoe WINIGRAD , Ardeshir GOLIAEI , Joseph AZOFEIFA , John K. DICKSON , Jason R. HARRIS , Eric MARTIN
IPC: A61K31/167 , A61K31/16 , A61K31/192 , A61K31/277 , A61K31/341 , A61K31/351 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/433 , A61K31/435 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/44 , A61K31/4439 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/4985 , A61K31/505 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/538 , A61K31/5415 , C07C233/06 , C07D217/18 , C07D217/20 , C07D239/545 , C07D265/36 , C07D279/16 , C07D471/04 , C07D487/04
CPC classification number: A61K31/167 , A61K31/16 , A61K31/192 , A61K31/277 , A61K31/341 , A61K31/351 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/433 , A61K31/435 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/44 , A61K31/4439 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/4985 , A61K31/505 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/538 , A61K31/5415 , C07C233/06 , C07D217/18 , C07D217/20 , C07D239/545 , C07D265/36 , C07D279/16 , C07D471/04 , C07D487/04
Abstract: Provided herein are inhibitors of GPX4, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the GPX4 inhibitory compounds for the modulation of ferroptosis and treatment of disease.
-
公开(公告)号:US20230142981A1
公开(公告)日:2023-05-11
申请号:US18150752
申请日:2023-01-05
Applicant: ARPEGGIO BIOSCIENCES, INC.
Inventor: Timothy READ , Joseph AZOFEIFA , Maria LAI , Joel BASKEN
IPC: C12N15/10 , C12Q1/6883 , C12N15/113 , C12Q1/6806
CPC classification number: C12N15/1093 , C12Q1/6883 , C12N15/113 , C12Q1/6806
Abstract: Provided herein are methods of identifying a marker for a biological interaction, the method comprising: quantifying genome-wide RNA expression in cells; exposing the cells to a perturbagen for a period of time sufficient to induce the biological interaction in the cells, wherein the induced biological interaction comprises inducing changes in RNA expression in the cells that are exposed to the perturbagen; quantifying genome-wide nascent RNA expression in the cells that were exposed to the perturbagen; calculating a difference in the genome-wide nascent RNA expression between (i) the genome-wide RNA expression in the cells absent the perturbagen and (ii) the genome-wide nascent RNA expression in the cells that were exposed to the perturbagen; and identifying the marker using the calculated difference in the genome-wide nascent RNA expression.
-
公开(公告)号:US20230160878A1
公开(公告)日:2023-05-25
申请号:US18150753
申请日:2023-01-05
Applicant: ARPEGGIO BIOSCIENCES, INC.
Inventor: Timothy READ , Joseph AZOFEIFA , Maria LAI , Joel BASKEN
IPC: C12Q1/26
CPC classification number: C12Q1/26 , C12Q2600/136 , G01N2333/902
Abstract: Provided herein are methods of screening a therapy for induction of ferroptosis, the method comprising: exposing a cell line to a potential therapy; measuring induction of Heme Oxygenase 1 (HMOX1) resulting from the exposing the cell line to the potential therapy; and identifying the potential therapy as passing or failing the screening of the therapy for induction of ferroptosis based on the measuring the induction of HMOX1.
-
公开(公告)号:US20230159916A1
公开(公告)日:2023-05-25
申请号:US18150750
申请日:2023-01-05
Applicant: ARPEGGIO BIOSCIENCES, INC.
Inventor: Timothy READ , Joseph AZOFEIFA , Maria LAI , Joel BASKEN
CPC classification number: C12N15/1093 , C40B30/06 , G01N33/5011
Abstract: Provided herein are methods of functionally linking two or more genetic loci of a genome of a cell sample, the method comprising: exposing the cell sample to a plurality of different stimuli in parallel for a period of time sufficient to elicit a transcriptional response from the cell sample directly or indirectly; performing a transcriptional run-on assay on the cell sample to yield labeled nascent RNA transcripts; isolating the labeled nascent RNA transcripts; preparing a nascent RNA library from the labeled nascent RNA transcripts; sequencing the nascent RNA library to produce sequencing reads and mapping the sequencing reads to a reference genome, wherein the sequencing reads that are mapped represent genomic locations in the cell sample where active transcription was occurring at the end of the period of time; and identifying active enhancers and correlating activity of the active enhancers with the active transcription of the cell samples.
-
-
-